<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Crofford, Leslie J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Best Practice Session—Fibromyalgia</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">30-31</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents new data that affect the assessment and management of fibromyalgia. Advancements in our understanding of the biology of fibromyalgia have led to a variety of new treatment approaches. However, the need to use an evidence-based approach to the pharmacologic treatment of pain and fatigue, which are central complaints of patients who sufferfrom fibromyalgia.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>